Constellation Pharmaceuticals
215 First Street
Suite 200
Cambridge
Massachusetts
02142
United States
Tel: 617-714-0555
Fax: 617-859-2891
Website: http://www.constellationpharma.com/
About Constellation Pharmaceuticals
78 articles about Constellation Pharmaceuticals
-
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
8/5/2020
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20
-
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
7/31/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs.
-
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock - June 17, 2020
6/17/2020
Constellation Pharmaceuticals, Inc. announced that it has priced an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $35.00 per share, for total gross proceeds of $192.5 million, before deducting underwriting discounts and commissions and expenses payable by Constellation.
-
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock - June 15, 2020
6/15/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.
-
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
6/12/2020
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of care
-
Constellation Pharmaceuticals to Participate in Investor Conference
6/10/2020
Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the Goldman Sachs 41st Annual Global Healthcare Conference at 8:00 AM EDT on June 11. A live audio webcast of Mr. Raythatha’s presenta
-
Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer
6/8/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jeffrey Humphrey, M.D., will join Constellation Pharmaceuticals as Chief Medical Officer. Dr. Humphrey is a medical oncologist with over twenty years’ experience in drug development. Most recently he was Chief Development Officer at Kyowa Kirin Co., where he over
-
Constellation Pharmaceuticals to Participate in Investor Conference
5/29/2020
Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the Jefferies Virtual Healthcare Conference at 2:30 PM EDT on June 2. A live audio webcast of Mr. Raythatha’s presentation and archives
-
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
5/14/2020
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeks SVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow fibrosis seen across treatment arms Additional data to be presented at EHA from ~50 1L and 70-80 2L patients CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical tr
-
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
5/6/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter 2020 financial results.
-
Constellation Pharmaceuticals to Participate in Two Investor Conferences in May 2020
5/5/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that the Company will participate in two upcoming virtual investor conferences. Jigar Raythatha, CEO
-
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
4/28/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 6, 2020, to discuss its first quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.
-
Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors
4/6/2020
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard Levy, M.D., has been appointed to its Board of Directors.
-
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
3/10/2020
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to previously expanded MANIFEST Cohorts 3 and 2A, now expanding Cohort 1A Planning update for MANIFEST and discussions with regulatory agencies about CPI-0610 around mid-year, additional MANIFEST update before yearend
-
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
3/6/2020
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 5:00 PM EDT on March 10, 2020, to discuss its fourth quarter results and progress in its clinical programs.
-
Constellation Pharmaceuticals to Present at Investor Conferences
2/26/2020
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present a company overview at the Cowen Health Care Conference in Boston at 1:30 PM EST on Monday, March 2, 2020
-
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
1/6/2020
A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.
-
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
12/13/2019
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $34.50 per share,
-
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12/10/2019
The offering is expected to close on December 13, 2019, subject to customary closing conditions.
-
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH
12/9/2019
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update of preliminary data from the MANIFEST clinical trial in oral and poster presentations at the annual meeting of the American Society of Hematology (ASH) in Orlando.